NCT05497284: To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF |
|
|
| Terminated | 2 | 46 | Europe, US, RoW | LTP001, Placebo, Standard of Care (SoC) | Novartis Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 08/24 | 09/24 | | |